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Abstract: (1) Background: Virtual screening studies on the therapeutically relevant proteins of the
severe acute respiratory syndrome Coronavirus 2 (SARS-CoV-2) require a detailed characterization
of their druggable binding sites, and, more generally, a convenient pocket mapping represents a
key step for structure-based in silico studies; (2) Methods: Along with a careful literature search
on SARS-CoV-2 protein targets, the study presents a novel strategy for pocket mapping based on
the combination of pocket (as performed by the well-known FPocket tool) and docking searches
(as performed by PLANTS or AutoDock/Vina engines); such an approach is implemented by the
Pockets 2.0 plug-in for the VEGA ZZ suite of programs; (3) Results: The literature analysis allowed the
identification of 16 promising binding cavities within the SARS-CoV-2 proteins and the here proposed
approach was able to recognize them showing performances clearly better than those reached by
the sole pocket detection; and (4) Conclusions: Even though the presented strategy should require
more extended validations, this proved successful in precisely characterizing a set of SARS-CoV-2
druggable binding pockets including both orthosteric and allosteric sites, which are clearly amenable
for virtual screening campaigns and drug repurposing studies. All results generated by the study
and the Pockets 2.0 plug-in are available for download.
Keywords: SARS-CoV-2; pocket search; pocket druggability; docking simulations; virtual screening;
blind docking
1. Introduction
The exploration of the potential binding cavities within a given target protein represents a key
step among the computational tasks, which follow the target identification [1]. After the experimental
resolution or the in silico modeling of the target structure, such a mapping enables the identification
of the most relevant binding sites for which virtual screening simulations or de novo rational design
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should allow the identification of promising hits. Clearly, a medium-size protein can have a large
number of cavities, which show different shapes (holes, clefts, pores, tunnels, etc.) as well as different
roles [2]. Therefore, the first crucial step in the cavity mapping is the recognition of those cavities that
are accessible and can have a role in modulating the protein activity. Yet again, not all the potentially
interesting cavities can be effectively engaged by interacting ligands. While playing a role in protein
activity, some cavities are indeed unable to generate stable complexes with (at least) small drug-like
molecules due to their structural, physicochemical, or electronic properties. This fact led to the concept
of pocket druggability, the evaluation of which should allow the identification of those cavities for
which the hit identification should be reasonably productive [3].
Hence, it comes as no surprise that a remarkable number of computational approaches have been
proposed in the last years with a view to mapping the cavities within a given protein structure and to
evaluating the resulting druggability. They comprise methods based on Voronoi tessellation [4], grid
search [5], surface analysis [6], void sphere clustering [7] or they can involve various combinations
of these [8]. Moreover, the increasing number of experimentally resolved protein structures allows
a markedly more accurate validation of these methods [9]. By using a purposely collected cavity
database, a recent benchmarking analysis compared some well-known approaches for mapping the
protein cavities and revealed that FPocket and GaussianFinder are those offering the best performances,
with FPocket being able to identify the highest number of correct cavities [10].
Even though the above-discussed methods to detect protein cavities also include an evaluation of
their druggability, other methods are specifically focused on the druggability analysis of the found
pockets. They can be based on the physicochemical and structural local properties of the cavities or the
comparison with homologous proteins or the sole sequence analysis. Often, these methods combine
various kinds of information and develop their predictions by using machine learning approaches [11].
To the best of our knowledge and although very often the detected pockets are further evaluated
by performing preliminary docking simulations using reference ligands, the combination of pocket
searches with systematic docking analyses as an automatic tool to find and to prioritize the target
cavities has never been proposed. Therefore, the present study describes Pockets 2.0, a plug-in
implemented in the VEGA ZZ suite of programs [12], which combines the FPocket method, chosen
due to its notable performances (see above) with docking simulations as performed by PLANTS [13]
or by AutoDock/Vina programs [14]. The overall Pockets 2.0 performances were then assessed by
comprehensively analyzing a dataset comprising all non-structural or therapeutically promising
SARS-CoV-2 proteins for which orthosteric and allosteric binding sites, as well as some potential
ligands, were derived by an extensive literature search focused on the homologous proteins. The dataset
includes both resolved structures and homology models, thus allowing potential differences in the
Pockets 2.0 performances between them to be revealed.
2. Results
2.1. Overview of the Available Data on SARS-CoV-2 Binding Pockets
Before applying the here proposed method to identify and to assess potentially druggable binding
pockets within the SARS-CoV-2 proteins, a careful literature search was performed. When the binding
pockets were not directly identifiable by the available structures, they were derived by comparing the
considered SARS-CoV-2 proteins with resolved homologous proteins. This study had two primary
objectives: 1) finding putative orthosteric and allosteric pockets by which to assess the performances
of the proposed method and 2) finding potential ligands (substrates, inhibitors or modulators) to be
used as probes during docking simulations. Not to mention that the here collected information is
relevant per se, since it affords a better understanding of the catalytic mechanism and (if present) of the
allosteric modulation for the analyzed enzymes and can guide the corresponding docking simulations.
Hence, this section reports the relevant information acquired during this literature analysis for some
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relevant SARS-CoV-2 proteins. All the information collected during such a comprehensive literature
analysis is compiled in Table 1.
Table 1. Orthosteric and allosteric binding sites for the therapeutically relevant protein targets as
derived from the literature search.
Protein Source a Function ReferenceProtein PDB Id Site Ligand
c Ref.
3CL-PRO See Table 2 protease —b —b orthosteric 3WL [15,16]
N-Protein 6M3M 6VYO Nucleocapsid protein HCoV-OC43
N-NTD
4LMC
orthosteric
C5P
[17]
4LM9 5GP
4LM7 U5P
4LI4 AMP
4KXJ P34
Nsp3 6W02 ADP ribosephosphatase — — orthosteric ADP ***
d
Nsp6 DN Membrane-spanningprotein
No experimental
information apart
from
mutants analysis
— allosteric K22 [18]
Nsp9 6W4B Replicase
Coronavirus
NSP9 1QZ8 orthosteric SO4 [19]
Type 2 rhinovirus
3C protease 1CQQ orthosteric AG7 [20]
Nsp12 7BV2
RNA-dependent RNA
polymerase (RdRp)
— — orthosteric F86 ***
Hepatitis C RdRp 2BRL allosteric1 (thumb) POO [21]
Hepatitis C NS5B
polymerase 2HAI alllosteric2 (thumb) PFI [22]
Hepatitis C NS5
polymerase 3HHK allosteric3 (palm) 77Z [23]
Nsp13 HM Helicase
RNA-Dependent
ATPase Upf1 2XZL orthosteric ADP-ALF [24]
Hepatitis C virus
NS3 protein 4B75 Allosteric 4VA [25]
Nsp14 HM Methyltransferase SARS-CoV 5C8S orthosteric SAH, G3A [26]
Nsp15 6W01 Endoribonuclease SARS-CoV 2H85 orthosteric U3M [27]
Nsp16 6WKS6W4H Methyltransferase — — orthosteric SAM, GTA ***
PL-pro 6W9C Papain-like protease SARS-CoV 3E9S orthosteric TTT ***
Spike Xray with ACE2 Viral entry glycoprotein — — Protein–protein interaction YMZ [28–36]
a For resolved proteins, the corresponding PDB Id is reported, while for modelled structures, HM and DN mean
homology modeling and de novo modeling, respectively. b — means that the binding site was directly identified
from the resolved protein SARS-CoV-2 structure. c The IUPAC name of the probe ligands can be found in the
Abbreviations. d *** indicates that the resolved SARS-CoV-2 protein structures are available in PDB, while the
corresponding paper is still unpublished.
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Table 2. Results of the pocket analysis as performed by Pockets 2.0 on the therapeutically relevant
protein targets. The first part of the Table includes data concerning the overall search (such as the
source of the analyzed protein, the probe ligand and the number of found pockets), while the second
part comprises data concerning the search for the correct pocket. In detail, the Table reports how the
correct pocket was ranked by FPocket and PLANTS alone and by consensus score, which combines
both searches. The volume and the ChemPLP score for the correct pocket are also listed.
Protein
Protein Data Data for the Search of the Correct Pocket
Source/ID Ligand NPockets
Rank by
Fpocket
Rank by
PLANTS
Rank by
Consensus
Volume
(Å3)
ChemPLP
(kcal/mol)
3CL-PRO
5R7Y 3WL 16 1 1 1 3604.93 −76.15
5R7z 3WL 16 1 1 1 4246.06 −73.85
5R80 3WL 20 2 2 1 1833.23 −76.48
5R81 3WL 17 1 1 1 3141.06 −80.27
5R82 3WL 19 1 4 1 3989.84 −68.23
5R83 3WL 21 1 1 1 4079.17 −77.59
5R84 3WL 21 1 1 1 2562.02 −80.88
6LU7 3WL 14 1 1 1 4239.62 −77.83
6MN2 dimer 3WL 80 1 1 1 3344.72 −86.30
6M03 3WL 24 3 3 3 2175.81 −69.70
6Y2E 3WL 18 1 4 1 2629.29 −75.02
6Y2F 3WL 20 1 1 1 2581.33 −77.61
6Y2G 3WL 16 2 3 2 5074.55 −75.78
6Y84 3WL 20 1 2 1 3068.30 −73.94
Nsp3 6W02 APR 6 2 1 1 2247.84 −119.05
Nsp6 DN K22
25 3 1 1 2364.82 −75.26
DN 27 4 1 1 3692.30 −76.86
Nsp9 6W4B AG7 13 2 3 1 2740.53 −97.41
Nsp12-Nsp7-Nsp8 7BV2 trimer
ATP (ortho)
79
1 2 1 4397.28 −94.18
POO/ PFI
(allo) 2 1 1 3545.24 −97.80
77Z (allo) 1 4 2 4397.28 −85.22
Nsp13 HM
ADP (ortho)
40
3 2 2 4359.36 −79.98
4VA (allo) 5 10 5 2526.96 −74.28
Nsp14-Nsp10 HM dimer
SAH
49
2 9 4 5307.98 −80.25
SAM 2 2 1 5307.98 −88.09
G3A 2 1 1 5307.98 −119.09
Nsp15 6W01 hexamer U3P 170 5 3 1 2792.58 −80.39
6VWW dimer U3P 52 6 1 3 2275.76 −81.75
Nsp16-Nsp10
6WKS dimer
SAM
63
1 8 1 4772.88 −88.43
GTA 1 1 1 4772.88 −118.80
6W4H dimer
SAM
31
1 1 1 3243.06 −87.81
GTA 1 2 1 3243.06 −112.33
N-protein 6M3M C5P, 5GP, U5P,
AMP, P34
7 3 2 2 1252.56 −66.69
6VYO 7 3 3 3 1961.99 −70.57
PL-Pro 6W95 TTT 23 3 2 1 2134.23 −94.17
SPIKE–ACE2
6LZG dimer
YMZ
56 2 2 1 4792.66 −80.66
6M0J dimer 58 1 5 1 4407.92 −74.29
6M17 hexamer 275 111
1
1
1
2 3767.99 −81.79
6VW1 dimer 61 1 2 1 4920.74 −77.78
Correctly Identified Pockets 20 18 30
Correct Pockets Ranked as #2 9 10 5
Correct Pockets Ranked as #3 6 5 3
Correct Rockets Out of the Podium 5 7 2
Average Rank 2.18 2.43 1.45
Precision 0.5 0.45 0.75
Accuracy 0.97 0.97 0.99
MCC 0.48 0.43 0.74
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The main protease (3-chymotrypsin like protein, 3CL-PRO) is a key enzyme involved in viral
replication and transcription. Hence, this is a very attractive antiviral target and several resolved
structures have been already released. Some resolved structures are in complex with inhibitors thus
allowing a precise characterization of its binding cavity. Similarly, screening studies proposed some
potential 3CL-PRO inhibitors including both covalent and non-covalent ligands [15]. Here, a total of 14
resolved SARS-CoV-2 3CL-PRO structures were analyzed (5R7Y, 5R7Z, 5R80, 5R81, 5R82, 5R83, 5R84,
6LU7, 6M2N, 6M03, 6Y2E [16], 6Y2F, 6Y2G, 6Y84).
The nucleocapsid protein (N-protein) of Coronaviruses is a structural protein, which packs the
RNA genome forming a helical nucleocapsid structure or ribonucleoprotein (RNP) complex [17].
Two X-ray structures of SARS-CoV-2 are already available (PDB Id: 6M3M and 6VYO) but in
their apo form. However, five N-protein resolved structures from Human coronavirus OC43
(HCoV-OC43) co-crystallized with different ligands within the RNA-binding site (i.e., C5P, 5GP,
U5P, AMP, P34 (inhibitor) with PDB Id: 4LMC, 4LM9, 4LM7, 4LI4, 4KXJ, respectively [37]) are available.
The binding site is extremely conserved, leading to easy identification of the corresponding pocket in
the SARS-CoV-2 protein.
The ADP ribose phosphatase nsp3 of SARS-CoV-2 was crystallized early this year (PDB Id: 6W02)
in complex with the substrate ADP ribose, thus allowing a precise characterization of its catalytic
cavity. Nsp3 is believed to play key roles in virus replication, which go beyond the simple phosphatase
activity, although many of its functions remain to be investigated [38].
Nsp6 is a membrane-spanning protein involved in the compartmentalized viral RNA synthesis [39].
Until now, no crystal structure was resolved but a theoretical model can be generated by de novo
modelling. Even though specific information concerning the nsp6 binding sites are not available,
a recent analysis of known SARS-CoV-2 mutants highlighted the key role of a cluster composed of
aromatic residues and located within the extracellular loop between the first two transmembrane
regions in reasonably determining activity and stability of the proteins, since it might be involved
in the interaction with the membrane of the endoplasmic reticulum [18]. Moreover, a potent nsp6
inhibitor (K22) was reported for several coronaviruses and its antiviral activity was ascribed to its
capacity to interfere with the interaction between nsp6 and the membrane structure [40].
The nsp9 replicase protein of SARS-CoV-2 was recently resolved (PDB Id: 6W4B). This enzyme is
believed to bind RNA-single strand in the viral replication complex [19,41]. So far, no proper binding
pockets have been identified on this protein. However, the crystal structure of nsp9 SARS-CoV (PDB
Id: 1QZ8 [20]) suggests that molecules could bind close to the RNA binding site. In detail, the putative
site for inhibitors can be derived by the observation that nsp9 is structurally homologous to the
subdomains of serine proteases, in particular to the second domain of coronavirus 3CLpros (PDB Id:
1P9U, in complex with the protease inhibitor PRD_000457) and to the first domain of human rhinovirus
3CLpros (PDB Id: 1CQQ, co-crystallized with RUPINTRIVIR a peptidomimetic inhibitor) [42].
Nsp12 is an RNA-dependent RNA polymerase (RdRp) and is the main enzyme responsible for
the RNA replication of the virus, making it an appealing target for the pharmacological treatment of
the SARS-CoV-2 infection. Two structures of SARS-CoV-2 nsp12 in complex with its cofactors nsp7
and nsp8 were recently resolved (PDB Id: 6M71 and 7BV2). As depicted by Figure 1, one of these
structures (i.e., 7BV2) is co-crystallized with the inhibitor remdesivir, allowing the precise identification
of the orthosteric site (Figure 1A). Furthermore, a search for allosteric pockets was also performed
since SARS-CoV nsp12 shows structural similarity with the RNA-dependent RNA polymerase of
Hepatitis C virus (HCV), called NS5B [43], as both enzymes share the well-known “hand” shape and
NS5B is regulated by allosteric modulation [44–46]. In detail, three allosteric sites were identified on
NS5B: two on the “thumb” (Figures 1B and 1C), and one on the “palm” (Figure 1D). These sites were
co-crystallized with three different inhibitors (PDB Id: 2BRL, 2HAI, and 3HHK, Table 1) [21–23,47].
All these resolved structures belong to the HCV genotype 1 for which allosteric modulation was best
established [48]. Thus, these crystal structures were utilized as a reference for identifying the putative
corresponding allosteric sites on the homology model of SARS-CoV-2 nsp12.
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steric site for nsp13 was also derived from the NS3 helicase of HCV (PDB Id: 4B75 [49]). The inhibitor 
binds at the interface between NS3 and NS4, preventing the interaction between the two proteins. 
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Figure 1. Identified binding sites ithin the resolved nsp12 structure (PDB Id: 7BV2): the orthosteric
cavity in complex with remdesevir (A) plus three potential allosteric sites, among which two are located
on the “thumb” as defined in their putative complexes with POO (B) and PFI (C) plus one site on the
palm in the predicted complex with 77Z (D).
The helicase nsp13 catalyzes the unwinding of oligonucleotides duplex into single strands. Given
its vital role in virus replication, this has been pointed out as a promising pharmacological target [24].
For this reason, a homology model was built using the crystal structure of MERS-CoV nsp13 (PDB Id:
5wwp [25]) as the template and we looked for possible binding sites. The orthosteric site was retrieved
from the resolved structure of the helicase Upf1 from Saccharomyces Cerevisiae (PDB Id: 2XZL [26])
which belongs to the Super Family 1 (SF1) of helicases, similarly to SARS-CoV nsp13. Upf1 is in
complex with RNA and ADP: AlF4−, which mimics the transition state of the ATP hydrolysis reaction.
The orthosteric site is highly conserved and a good agreement between the binding site residues of
the crystal structure and the SARS-CoV-2 homology model was found. A putative allosteric site for
nsp13 was also derived from the NS3 helicase of HCV (PDB Id: 4B75 [49]). The inhibitor binds at
the interface between NS3 and NS4, preventing the interaction between the two proteins. Given the
similarity between the structures and the involved residues, a similar allosteric site was also supposed
for nsp13, which could be responsible for modulating the interaction with nsp12.
Nsp14 is a (guanine-N7) methyltransferase (N7-MTase) for mRNA capping. Currently, no resolved
structure for SARS-CoV-2 nsp14 is available, but the protein can be modeled by homology techniques
as the heterodimer nsp10-nsp14, using the available crystal structures of the SARS-CoV nsp10-nsp14
heterodimer (PDB Id: 5C8S [27]) as the template. Luckily, the template was resolved in complex
with the functional ligands involved in the catalytic reactions (namely the GpppA substrate and the
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demethylated SAH cofactor) thus allowing a precise characterization of the catalytic pocket within the
modeled SARS-CoV-2 nsp14 structure.
Nsp15 is a uridylate-specific endoribonuclease, the structure of which was recently resolved
in complex with citrate (PDB Id: 6W01 [50]). The orthosteric cavity was derived by comparison
with the corresponding resolved structures from SARS-CoV (PDB Id: 2H85 [51]). Even though both
structures were in their apo form, the orthosteric cavity was identified based on sequence alignment
and mutational analyses within the C-terminal domain. As depicted in Figure 2, the so identified
cavity was finally verified by preliminary docking simulations with the uridine 3′-phosphate ligand,
which produced a pose in encouraging agreement with that proposed for SARS-Cov and Middle East
respiratory syndrome coronavirus (MERS-Cov) nsp1. [52,53].
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Figure 2. Identified orthosteric cavities within the nsp14 in complex with its ligands, GpppA,
and SAH (A), as well as within the C-terminal domain of nsp15 in the putative complex with its
substrate uridine 3′-phosphate (B). In the inlet of 2B, the key contacts stabilizing the complex.
s 16 is a 2′ O-methyltransferase [54] and two resolved structures are available in complex
(PDB Id: 6W4H and 6WKS) with its cofactor nsp10, which is essential for the activity.
The first structure is co-crystallized with SAM, while the second one includes both SAM and
the P1-7-methylguanosine-P3-adenosine-5′,5′-triphosphate (GTA) substrate, thus allowing precise
identification of the overall catalytic pocket.
The papain-like protease of SARS-CoV-2 (PL-Pro) [28] was recently resolved (PDB Id: 6W9C)
in its apo form. A putative binding cavity was derived by the comparison with the corresponding
structure from SARS-CoV co-crystallized with a potent inhibitor (PDB Id: 3E9S in complex with TTT).
last S S- o -2 protein that has attracte great interest in its role in the viral entry is the
Spike protein, the receptor-binding do ain ( B ) of hich is recognized by the hu an receptor
angiotensin-converting enzy e 2 ( E2) [29]. ence, different resolved proteins of the sole tri eric
S S- o -2 spike protein (P B Id: 6L , 6L T [30], 6 SB [31], 6 [32], 6 B [33]) as ell as of
its B in co plex ith E2 (P B Id: 6L [34], 6 0J [35], 6 17 [36], 6 1 [55]) ere recently
reported. Rather than druggable pockets, these complexes allow a precise characterization of the
protein–protein interactions by revealing the key regions involved in spike–ACE2 recognition. In the
follo ing docking si ulations, the pocket analysis as perfor ed by using efloquine as the probe
ligand since it as recently reported to be able to inhibit the spike– E2 interaction [56].
Finally and to the best of our knowledge, no binding sites can be identified by analyzing
homologous proteins for the non-structural proteins nsp2, nsp4, nsp7-nsp8, and nsp10. Similarly,
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the membrane protein (M-protein) and the Open Reading Frame (ORF) proteins (ORF3a, 6, 7a, 7b,
8, 10) are structural proteins for which no druggable site can be found [57].
Such a preliminary analysis allowed the identification of 16 binding pockets within 12 different
SARS-CoV-2 proteins: in detail, the orthosteric pocket was identified in all proteins, apart from nsp6
and the Spike protein where the hot spots for the ACE2 interaction were yet detected, an allosteric
site was also recognized within nsp6 and nsp13, while at least three allosteric pockets were identified
for nsp12. In the following part of the study, the identified binding pockets will be used as a test
set to validate the performances of Pockets2.0 by evaluating its capacity to recognize them as the
best pocket when ranked by combining pocket and docking searches compared to the two methods
taken separately (as reported in Table 2). For simplicity, the identified binding pockets will be named
hereinafter as the “correct pockets”.
2.2. Pockets 2.0 Performances
As mentioned above, the performances of combining pocket searches and docking calculations
were assessed by evaluating the Pockets 2.0 capacity to recognize the 16 previously identified correct
pockets as derived from literature search and structural comparisons. Since in several cases, more
than one structure was analyzed for each protein (for example, 14 resolved structures were analyzed
for 3CL-PRO) and/or more than one ligand was considered for each pocket, this benchmarking study
involved 40 pocket searches overall.
Table 2 shows all the investigated proteins with the corresponding detected pockets and the
considered probe ligands. Even though the considered 3CL-PRO structures were resolved in complex
with different ligands, the pocket searches were repeated by always using the non-covalent inhibitor
included in the 6MN2 structure (i.e., 5,6,7-trihydroxy-2-phenyl-4H-chromen-4-one, 3WL) to avoid
covalent ligands and to obtain comparable results.
In order to evaluate the correctness of the predicted best pocket, an unbiased approach, which is
amenable when analyzing co-crystallized proteins, might be based on rmsd analysis or on volume
overlapping between the bound ligand and the pocket shape (as generated by FPocket) or the
docked probe molecule (as computed by PLANTS). Unfortunately, the reported analysis involves both
theoretical models and resolved proteins with no bound ligands. In these cases, the arrangement of the
orthosteric and allosteric binding sites was argued by structural comparison with homologous proteins
(as described above) and there are no reference bound ligands for which rmsd or volume overlapping
can be evaluated. Hence, the identification of the correct pockets is here based on the identification of
some key residues lining the binding site and the detected pockets are evaluated by considering their
distance to these key residues. Clearly, the correct pocket is the closest one to the key residues and
the binding site is defined as correctly recognized if the closest pocket is ranked as the first pocket
(by FPocket, by PLANTS and by consensus score). For example, the performances for 3CL-PRO were
evaluated by considering the ranking of the detected pocket closest to the catalytic Cys145 residue.
As explained under Methods, docking simulations were systematically performed within all
found pockets using PLANTS. In order to evaluate the Pockets2.0 capacity to recognize the correct
pockets, Table 2 also compiles their ranking as based on the FPocket scores, on the docking scores and
on the consensus of both scores. For each pocket search, Table 2 reports the volume and the ChemPLP
scores as computed by PLANTS for the corresponding correct pockets.
The analysis of the so obtained performances allows for some meaningful considerations. Above
all, the combination of FPocket searches and docking calculations leads to a marked improvement
in the number of correctly identified pockets since the consensus score recognizes 30 correct pockets
out of 40, with an overall satisfactory precision equal to 0.75. Even though the pocket searches
involving theoretical models are markedly lower compared to those on the resolved proteins (7 vs. 33),
the obtained results do not seem to be influenced by the source of the protein structure since the correct
cavity was ranked as best pocket within theoretical models in four cases out of seven.
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In detail, FPocket alone was able to recognize one half of the correct pockets (20 out of 40, precision
= 0.50), a performance which is in line with that reported by the above mentioned benchmarking study
for FPocket when used without repetitions [10]. The performances of docking scores alone are slightly
worse than those reached by FPocket (18 out of 40, precision = 0.45) even though it should be noted
that docking simulations are not blindly performed on all the protein surfaces but they are focused on
the pockets previously detected by FPocket and thus the docking performances unavoidably benefit
(at some extent) of the encouraging results offered by FPocket. That being said, one may observe
that in 24 cases (out of 40) the rankings of the correct pocket as computed by FPocket and docking
simulations do not match and this underlines that docking simulations, while benefitting from the
good FPocket performances, encode for additional information that is not simply ascribable to the
pocket’s local features.
Interestingly, the consensus score clearly reduces the number of cavities that are incorrectly ranked
as second or third cavity compared to the Fpocket or docking scores alone. This indicates that the
combination of the two scores allows the pockets that were incorrectly ranked by the two search
methods alone to be promoted as the best pocket. In detail, the analysis of the 30 pockets correctly
identified by the consensus score reveals that only in 11 cases (out of 11), the correct pockets were
ranked as the best cavity by both methods, in 13 cases (out of 16), the correct pockets were ranked
as non-best solutions by one method, and in 6 cases (out of 13), the correct pockets were ranked as
non-best solutions by both methods. These results reveal that in 19 cases (out of 29), the combination of
both methods played a crucial role in identifying the correct pocket, thus emphasizing the remarkable
potential of the here proposed combined approach. Intriguingly, the above reported results also allow
for another interesting interpretation since they reveal that the correct cavity is successfully recognized
in 100% of the cases when both methods ranked it as the best solution. The probability of recognizing
the correct cavity decreases to 81% if at least one method ranked it as the best pocket, dropping to
46% if both methods are unable to recognize it as the best solution. These results suggest that the
combination of pocket and docking searches affords a mutual validation, which increases the reliability
of the predicted pockets.
The validation of the here proposed method can be also assessed by considering that the performed
pocket searches involved a total of 1364 cavities, which can be subdivided into 40 correct pockets
and 1324 incorrect pockets. This means analyzing confusion matrices including a) 20, 18 and 30 true
positives; b) 20, 22 and 10 false positives and false negatives and c) 1304, 1302 and 1314 true negatives
for Fpocket, PLANTS and consensus rankings, respectively. While considering such an unbalanced
dataset, the increase in the MCC value as obtained by combining pocket and docking search (from 0.48
to 0.74) affords a further confirmation of the potential of the here proposed approach.
A detailed analysis of the investigated proteins reveals that the pocket search for the 14 resolved
3CL-PRO structures is substantially driven by FPocket, which indeed recognizes the correct pocket
in 11 cases. These notable FPocket performances can be here explained by considering that its score,
while also including parameters related to the local features of the pockets, tends to favor the large
pockets. While considering a certain degree of heterogeneity among the reported pocket volumes,
which is explainable by considering that even small changes in the arrangement of the lining side
chains can induce a different pocket fragmentation by FPocket, the 3CL-PRO catalytic cavity is by far
the largest pocket and thus is almost always correctly recognized by FPocket. When discarding the
3CL-PRO structures, the results markedly change since FPocket is able to recognize the correct pocket
only in 9 cases out of 26, and the pocket search appears to largely benefit from docking simulations
as evidenced by the fact that consensus score correctly recognizes 18 pockets out of 26. These last
results emphasize how the combination of pocket and docking searches could be particularly effective
when exploring complex proteins endowed with narrow binding cavities, and indeed it appears truly
productive when looking for allosteric binding sites, as seen for nsp6 and nsp12.
The analysis of the pockets for nsp12 and the Spike protein deserves a separate description.
With regard to the nsp12 allosteric cavities, the two cavities on the thumb region can be identified with
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difficulty due to the folding of some loops, which partly occupy the cavities, thus leading to their
unsatisfactory fragmentation. Hence, the cavity n. 2 was selected since it is large enough to encompass
both allosteric sites while not matching either one specifically. Again, the allosteric cavity on the palm
region is merged to the orthosteric site, thus generating a unique very large binding site (pocket n. 1),
which can suggest the design of bivalent ligands able to interact with both subpockets.
Concerning the Spike protein, all simulations involved the resolved complexes of Spike–ACE2
even though the pockets detected on the ACE2 surface were discarded from the analyses. Though to
test the Pockets 2.0 performances, the analysis of the largest Spike–ACE2 complex (PDB Id: 6M17),
a hexamer that also includes two chains of the sodium-dependent neutral amino acid transporter
B(0)AT1, was also repeated by considering all 275 detected pockets. Gratifyingly, FPocket ranks the
correct pocket in the eleventh position while docking simulations proved successful to recognize
the correct pocket even in such a challenging situation, and the pocket was ranked as the second
one by consensus score, thus further confirming the key role of docking simulations to identify the
druggable cavities.
With regard to the badly predicted pockets, there are only two cases in which the correct pocket is
ranked off the podium, namely the allosteric site of nsp13 and the orthosteric cavity of the nsp10-14
for the SAH ligand. The unsatisfactory prediction of the nsp13 allosteric pocket can be justified
by considering that this binding site should be located at the interface between nsp13 and nsp12
(see above), and thus cannot be properly mapped by considering only nsp13. Again, the wrong
prediction for the nsp10-14 heteromer is due to unsuitable docking results, which can be rationalized
by considering that SAH is in fact the reaction product and indeed the performances significantly
enhance when considering SAM, which is the true cofactor.
3. Materials and Methods
3.1. Protein Structures
Available experimental structures were downloaded from the PDB (the corresponding PDB
Ids are reported in Table 2). The two analyzed homology models for nsp13 and the nsp10-nsp14
heteromer were retrieved by the dedicated SWISS-MODEL page which comprises models for the
full SARS-CoV-2 proteome (https://swissmodel.expasy.org/repository/species/2697049). Homology
modelling (HM) was performed by SWISS-MODEL [58]. SWISS-MODEL identifies suitable homologues
to be used as modelling templates with BLAST [59] and HHblits [60] in the SWISS-MODEL Template
Library. Model building using the identified templates and their associated target-template sequence
alignments was delegated to the ProMod3 modelling engine (Swiss Institute of Bioinformatics and
Biozentrum, Basel, Basel), which performs the following steps: (1) extraction of structural information
from the template; (2) loop modelling using an internal loop database or Monte Carlo sampling;
(3) side chain modeling using an internal backbone-dependent rotamer library and optimization with
the graph-based TreePack algorithm [61] minimizing the SCWRL4 energy function [62]; (4) energy
minimization using OpenMM [63] with the CHARMM force field [64]. The global and per-residue
model quality of the final models was assessed by the QMEAN scoring function [65] and QMEANDisCo,
respectively [66]. The homology models have been deposited in the ModelArchive database with
the unique stable accession codes (DOI) https://modelarchive.org/doi/10.5452/ma-epkbe for nsp13
and https://modelarchive.org/doi/10.5452/ma-3rg44 for the nsp10-14 heteromer. De novo models
(DN) for nsp6 were obtained from the Feig group (https://github.com/feiglab/sars-cov-2-proteins) [67].
Specifically, the FeigLab and AlphaFold-refined models of nsp6 were used.
3.2. Preliminary Simulations
Be they resolved or modelled, all simulated proteins were prepared by adding (when necessary)
the hydrogen atoms to remain compatible at physiological pH and by removing (when present) water
solvents, crystallization additives, and bound ligands. The protein structures were then minimized
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by using Namd2 (NIH Center for Macromolecualr Modeling & Bioinformatics, Urbana-Champaign,
Illinois, USA) [68] and by keeping the backbone atoms fixed to preserve the resolved or predicted
folding. In detail, the minimizations were carried out by using the conjugate gradient algorithm
until RMS = 0.01 kcal mol-1Å-1 (maximum number of steps = 10000) with the CHARMM force field
and the Gasteiger’s atomic charges. All tested probe ligands were optimized by PM7 semi-empirical
calculations [69]. When necessary to further assess the pocket reliability (as in the case of nsp15),
preliminary docking simulations were performed using PLANTS (Theoretische Chemische Dynamik,
Konstanz, Germany) [13] and focusing the search on a 10 Å radius sphere around the identified key
residues. For each simulation, 10 poses were generated and ranked by ChemPLP with speed equal to 1.
3.3. The Pockets 2.0 Approach
Starting from release 2.4, the VEGA ZZ suite of programs (Drug Design Laboratory, Milan, Italy)
comprises a graphical interface to FPocket (named Pocket plug-in) [70]. FPocket (Ressource Parisienne
en BioInformatique Structurale, Paris, France) is a well known software to detect protein cavities, which
is based on an extremely optimized algorithm for Voronoi tessellation, the performances of which
allow even complex macromolecules to be rapidly analyzed [4]. Here a new version of the plug-in for
FPocket (named Pockets 2.0) is described. For a better exploration of the protein cavities, this combines
the already implemented cavity mapping as performed by Fpocket with docking calculations with
probe molecule(s) using AutoDock/Vina or PLANTS docking programs. To optimize the ranking of the
explored cavities, Pockets 2.0 can utilize both Fpocket and docking scores by calculating customizable
consensus scores.
Figure 3 shows the Pockets 2.0 workflow for the identification and prioritization of the potential
binding sites for a given protein. The plug-in accepts as primary input the 3D coordinates of the target
protein, which can be in any file format supported by the VEGA ZZ program. The input protein
structure is firstly analyzed by FPocket, which finds and ranks the cavities according to its internal
score. Along with the scores computed by FPocket, the plug-in adds information concerning the
geometric features of each pocket, which will be useful for the following docking calculations.Int. J. Mol. Sci. 2020, 21, x FOR PEER REVIEW 13 of 19 
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Once the pockets are calculated and analyzed, they can undergo the docking simulations. To do
this, the selected ligand(s) should be suitably prepared depending on the chosen docking program.
After setting the docking parameters, the simulations are automatically performed on all selected
pockets using all collected probe ligands. Based on all computed scores, user-defined consensus
functions can be calculated to afford a combined ranking of all cavities. In the here described analysis
of the SARS-CoV-2 proteins, the consensus score is computed by summing the ranks obtained by
sorting the overall FPocket scores and the ChemPLP docking scores from best to worst.
Along with the interactive inspection of the found pockets and the corresponding ligand poses
within the VEGA ZZ graphical interface, the Pockets 2.0 plug-in generates a set of additional output
files regarding the computed poses for each pocket and the corresponding score values.
3.4. Pocket Search and Analyses
For the here performed analyses, the pocket search was performed by applying the default settings
of FPocket (e.g., minimum and maximum radius of alpha spheres equal to 3 Å and 6 Å, respectively)
with the only exception of the minimum number of spheres to define a pocket that was set equal to 30
(instead of 35) for a more exhaustive analysis even of the small cavities. For each protein, all found
cavities underwent docking simulations using PLANTS. In detail, the search was focused within the
corresponding spheres as derived from FPocket analysis by increasing their radius of 3 Å to completely
encompass the entire binding cavity. For each simulated ligand and each explored cavity, one pose was
generated by using the PLANTS_ChemPLP scoring function with speed equal to 1. In all the analyses,
the consensus function of each pocket was computed by combining the overall FPocket score with the
ChemPLP score. When more than one ligand was used as a probe for a pocket, the consensus score
involves the average of the corresponding ChemPLP scores. Since almost all the analyzed SARS-CoV-2
proteins are enzymes with various catalytic activities, the performances of the here presented combined
approach was preliminarily assessed, also considering a set of resolved GPCRs, the evaluation of
which was reported in the Supporting Information. As summarized in Table S1, the obtained results
also afford an encouraging validation with this class of proteins since the combination of pocket and
docking search was able to identify the correct pocket with an overall precision equal to 0.91, even
greater than that obtained with the SARS-CoV-2 targets.
4. Conclusions
The study had two primary objectives: characterizing the druggable binding sites within the
therapeutically relevant SARS-CoV-2 proteins as well as presenting and validating a novel strategy
to search and prioritize the protein pockets by using the identified SARS-CoV-2 sites as a test set.
Concerning the first objective, an extensive literature search combined with the comparison with
homologous proteins allowed precise identification of 16 druggable pockets within 12 different
SARS-CoV-2 proteins, including four allosteric sites. In this context, nsp12 represents a very interesting
target since its homology with the corresponding HCV enzymes allowed the identification of at least
three allosteric pockets, which can play key roles in determining the nsp12 activity as well as its
interactions with the cofactor proteins.
Concerning the second objective, the study reports the Pockets 2.0 plug-in as implemented in the
VEGA ZZ suite of programs, which automatically combines the pocket search, as performed by FPocket,
with docking simulations by using representative probe ligands and PLANTS or AutoDock/Vina as
docking engines. The combination of the FPocket and docking scores by calculating customizable
consensus scores leads to a significant increase in the correctly identified binding sites compared to the
FPocket and docking scores alone, and this enhancement appears to be truly relevant when considering
the MCC values which, while considering the dataset unbalancing, show an increase of 35% when
combining pocket and docking searches.
Again, an ancillary analysis involving an extended set of aminergic resolved GPCRs (see Supporting
Information) revealed that the here proposed approach provides even better performances with this
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class of therapeutically relevant proteins. Clearly, these encouraging results should be corroborated by
more extended analysis, including different proteins of increasing complexity, to verify the general
applicability of this strategy. Notably and since docking simulations can involve more than one ligand,
Pockets 2.0 can be also used as a powerful tool to perform focused blind docking simulations by
which even extended ligand datasets can be simultaneously docked into different potentially relevant
binding pockets.
All prepared protein and ligand structures, as well as all files generated by Pockets 2.0 searches,
are available at http://www.exscalate4cov.network. The repository will be periodically updated by
including the pocket mapping for the new available target proteins. The homology models have
been deposited in the ModelArchive database with the unique stable accession codes (DOI) https:
//modelarchive.org/doi/10.5452/ma-epkbe for nsp13 and https://modelarchive.org/doi/10.5452/ma-3rg44
for the nsp10-14 heteromer. The Pockets 2.0 plug-in is freely available within the VEGA ZZ suite of
programs at http://www.vegazz.net.
Supplementary Materials: The following are available online at http://www.mdpi.com/1422-0067/21/14/5152/s1,
Table S1: Results of the pocket analysis as performed by Pockets 2.0 on the collected GPCR targets. The Pockets
2.0 performances were evaluated by considering its capacity to identify the orthosteric and allosteric sites within
the selected GPCR complexes.
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Abbreviations
3WL 5,6,7-trihydroxy-2-phenyl-4H-chromen-4-one
4VA (2S)-4-amino-N-[(1R)-1-(4-chloro-2-fluoro-3-phenoxyphenyl)propyl]-4-oxobutan-2-aminium
5GP guanosine-5’-monophosphate
77Z
2-({(3R)-3-[(3S)-1-(3-methylbutyl)-2,4-dioxo-1,2,3,4-tetrahydroquinolin-3-yl]-1,1-dioxido-
3,4-dihydro-2H-1,2,4-benzothiadiazin-7-yl}oxy)acetamide
ACE2 angiotensin-converting enzyme 2
AG7
4-{2-(4-fluoro-benzyl)-6-methyl-5-[(5-methyl-isoxazole-3-carbonyl)-amino]-4-oxo
-heptanoylamino}-5-(2-oxo-pyrrolidin-3-yl)-pentanoic acid ethyl ester
C5P cytidine-5’-monophosphate
G3A guanosine-P3-adenosine-5’,5’-triphosphate
GTA P1-7-methylguanosine-P3-adenosine-5’,5’-triphosphate
HCV Hepatitis C virus
K22
(Z)-N-(3-(4-(4-bromophenyl)-4-hydroxypiperidin-1-yl)-3-oxo-1-phenylprop-1-en-2-yl)
benzamide
MERS-Cov Middle-East Respiratory Syndrome Coronavirus
MGT 7N-methyl-8-hydroguanosine-5’-triphosphate
N7-MTase N-7 Methyl transferase
NSP Non-structural protein
ORF Opening Reading frame
P34 2-(dimethylamino)-N-(6-oxo-5H-phenanthridin-2-yl)acetamide (PJ34)
PFI (6S)-6-cyclopentyl-6-[2-(3-fluoro-4-isopropoxyphenyl)ethyl]-4-hydroxy-5,6-dihydro-2h-pyran-2-one
RdRp RNA-dependent RNA polymerase
PL-Pro Papain-like protease
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POO
3-cyclohexyl-1-(2-{methyl[(1-methylpiperidin-3-yl)methyl]amino}-2-oxoethyl)-2-phenyl
1H-indole-6-carboxylic acid
RBD receptor binding domain
SAH S-Adenosyl homocysteine
SAM S-Adenosyl methionine
SARS-CoV Severe acute respiratory syndrome coronavirus
SARS-CoV-2 Severe acute respiratory syndrome coronavirus 2
TTT 5-amino- 2-methyl-N-[(1R)-1-naphthalen-1-ylethyl]benzamide
U3P uridine-3’-monophosphate
U5P uridine-5’-monophosphate
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